Top

Published in:

01-06-2018 | Commentary

Genetics of personalized medicine: cancer and rare diseases

Authors: Inês Teles Siefers Alves, Manuel Condinho, Sónia Custódio, Bruna F. Pereira, Rafael Fernandes, Vânia Gonçalves, Paulo J. da Costa, Rafaela Lacerda, Ana Rita Marques, Patrícia Martins-Dias, Gonçalo R. Nogueira, Ana Rita Neves, Patrícia Pinho, Raquel Rodrigues, Eva Rolo, Joana Silva, André Travessa, Rosário Pinto Leite, Ana Sousa, Luísa Romão

Published in: Cellular Oncology | Issue 3/2018

Abstract

The 21st annual meeting of the Portuguese Society of Human Genetics (SPGH), organized by Luísa Romão, Ana Sousa and Rosário Pinto Leite, was held in Caparica, Portugal, from the 16th to the 18th of November 2017. Having entered an era in which personalized medicine is emerging as a paradigm for disease diagnosis, treatment and prevention, the program of this meeting intended to include lectures by leading national and international scientists presenting exceptional findings on the genetics of personalized medicine. Various topics were discussed, including cancer genetics, transcriptome dynamics and novel therapeutics for cancers and rare disorders that are designed to specifically target molecular alterations in individual patients. Several panel discussions were held to emphasize (ethical) issues associated with personalized medicine, including genetic cancer counseling.

E.T. Wang, R. Sandberg, S. Luo, I. Khrebtukova, L. Zhang, C. Mayr, S.F. Kingsmore, G.P. Schroth, C.B. Burge, Alternative isoform regulation in human tissue transcriptomes. Nature 456, 470–476 (2008)CrossRefPubMedPubMedCentral

Q. Pan, O. Shai, L.J. Lee, B.J. Frey, B.J. Blencowe, Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 40, 1413–1415 (2008)CrossRefPubMed

T. Maniatis, B. Tasic, Alternative pre-mRNA splicing and proteome expansion in metazoans. Nature 418, 236–243 (2002)CrossRefPubMed

D.L. Bentley, Rules of engagement: co-transcriptional recruitment of pre-mRNA processing factors. Curr. Opin. Cell Biol. 17, 251–256 (2005)CrossRefPubMed

J.P. Staley, C. Guthrie, Mechanical devices of the spliceosome: motors, clocks, springs, and things. Cell 92, 315–326 (1998)CrossRefPubMed

Z. Zhou, L.J. Licklider, S.P. Gygi, R. Reed, Comprehensive proteomic analysis of the human spliceosome. Nature 419, 182–185 (2002)CrossRefPubMed

P.J. da Costa, J. Menezes, L. Romão, The role of alternative splicing coupled to nonsense-mediated mRNA decay in human disease. Int. J. Biochem. Cell Biol. 91, 168–175 (2017). https://doi.org/10.1016/j.biocel.2017.07.013 CrossRefPubMed

C.J. David, J.L. Manley, Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes Dev. 24, 2343–2364 (2010)CrossRefPubMedPubMedCentral

B. Sumithra, U. Saxena, A.B. Das, Alternative splicing within the Wnt signaling pathway: role in cancer development. Cell. Oncol. 39, 1–13 (2016)CrossRef

10.

M. Imielinski, A.H. Berger, P.S. Hammerman, B. Hernandez, T.J. Pugh, E. Hodis, J. Cho, J. Suh, M. Capelletti, A. Sivachenko, C. Sougnez, D. Auclair, M.S. Lawrence, P. Stojanov, K. Cibulskis, K. Choi, L. de Waal, T. Sharifnia, A. Brooks, H. Greulich, S. Banerji, T. Zander, D. Seidel, F. Leenders, S. Ansén, C. Ludwig, W. Engel-Riedel, E. Stoelben, J. Wolf, C. Goparju, K. Thompson, W. Winckler, D. Kwiatkowski, B.E. Johnson, P.A. Jänne, V.A. Miller, W. Pao, W.D. Travis, H.I. Pass, S.B. Gabriel, E.S. Lander, R.K. Thomas, L.A. Garraway, G. Getz, M. Meyerson, Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107–1120 (2012)CrossRefPubMedPubMedCentral

11.

J. Hernández, E. Bechara, D. Schlesinger, J. Delgado, L. Serrano, J. Valcárcel, Tumor suppressor properties of the splicing regulatory factor RBM10. RNA Biol. 13, 466–472 (2016)CrossRefPubMedPubMedCentral

12.

E.G. Bechara, E. Sebestyén, I. Bernardis, E. Eyras, J. Valcárcel, RBM5, 6, and 10 differentially regulate NUMB alternative splicing to control cancer cell proliferation. Mol. Cell 52, 720–733 (2013)CrossRefPubMed

13.

L. Wurth, P. Papasaikas, D. Olmeda, N. Bley, G.T. Calvo, S. Guerrero, D. Cerezo-Wallis, J. Martinez-Useros, M. García-Fernández, S. Hüttelmaier, M.S. Soengas, F. Gebauer, UNR/CSDE1 drives a post-transcriptional program to promote melanoma invasion and metastasis. Cancer Cell 30, 694–707 (2016)CrossRefPubMed

14.

A.R. Morris, N. Mukherjee, J.D. Keene, Systematic analysis of posttranscriptional gene expression. Wiley Interdiscip. Rev. Syst. Biol. Med. 2, 162–180 (2010)CrossRefPubMed

15.

L. Wurth, F. Gebauer, RNA-binding proteins, multifaceted translational regulators in cancer. Biochim. Biophys. Acta-Gene Regul. Mech. 1849, 881–886 (2015)CrossRef

16.

P. Papasaikas, J.R. Tejedor, L. Vigevani, J. Valcárcel, Functional splicing network reveals extensive regulatory potential of the core spliceosomal machinery. Mol. Cell 57, 7–22 (2015)CrossRefPubMed

17.

A.K. Goroncy, S. Koshiba, N. Tochio, T. Tomizawa, M. Inoue, S. Watanabe, T. Harada, A. Tanaka, O. Ohara, T. Kigawa, S. Yokoyama, The NMR solution structures of the five constituent cold-shock domains (CSD) of the human UNR (upstream of N-ras) protein. J. Struct. Funct. Genom. 11, 181–188 (2010)CrossRef

18.

G. Triqueneaux, M. Velten, P. Franzon, F. Dautry, H. Jacquemin-Sablon, RNA binding specificity of Unr, a protein with five cold shock domains. Nucleic Acids Res. 27, 1926–1934 (1999)CrossRefPubMedPubMedCentral

19.

D. Huang, H. Pospiech, T. Kesti, J.E. Syva, Structural organization and splice variants of the POLE1 gene encoding the catalytic subunit of human DNA polymerase ε. Biochem. J. 339, 657–665 (1999)CrossRefPubMedPubMedCentral

20.

C. Palles, J.B. Cazier, K.M. Howarth, E. Domingo, A.M. Jones, P. Broderick, Z. Kemp, S.L. Spain, E.G. Almeida, I. Salguero, A. Sherborne, D. Chubb, L.G. Carvajal-Carmona, Y. Ma, K. Kaur, S. Dobbins, E. Barclay, M. Gorman, L. Martin, M.B. Kovac, S. Humphray, A. Lucassen, C.C. Holmes, D. Bentley, P. Donnelly, J. Taylor, C. Petridis, R. Roylance, E.J. Sawyer, D.J. Kerr, S. Clark, J. Grimes, S.E. Kearsey, H.J.W. Thomas, G. McVean, R.S. Houlston, I. Tomlinson, Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat. Genet. 45, 136–144 (2013)CrossRefPubMed

21.

M.M. Hahn, R.M. de Voer, N. Hoogerbrugge, M.J.L. Ligtenberg, R.P. Kuiper, A. Geurts van Kessel, The genetic heterogeneity of colorectal cancer predisposition - guidelines for gene discovery. Cell. Oncol. 39, 491–510 (2016)CrossRef

22.

D. Chubb, P. Broderick, S.E. Dobbins, M. Frampton, B. Kinnersley, S. Penegar, A. Price, Y.P. Ma, A.L. Sherborne, C. Palles, M.N. Timofeeva, D.T. Bishop, M.G. Dunlop, I. Tomlinson, R.S. Houlston, Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat. Commun. 7, 11883 (2016)CrossRefPubMedPubMedCentral

23.

K. El Bairi, A.H. Kandhro, A. Gouri, W. Mahfoud, N. Louanjli, B. Saadani, S. Afqir, M. Amrani, Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. Cell. Oncol. 40, 105–118 (2017)CrossRef

24.

A. Chavez-Gonzalez, B. Bakhshinejad, K. Pakravan, M.L. Guzman, S. Babashah, Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. Cell. Oncol. 40, 1–20 (2017)CrossRef

25.

M. Yousefi, T. Bahrami, A. Salmaninejad, R. Nosrati, P. Ghaffari, S.H. Ghaffari, Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options. Cell. Oncol. 40, 419–441 (2017)CrossRef

26.

P.O. Pietarinen, C.A. Eide, P. Ayuda-Durán, S. Potdar, H. Kuusanmäki, E.I. Andersson, J.P. Mpindi, T. Pemovska, M. Kontro, C.A. Heckman, O. Kallioniemi, K. Wennerberg, H. Hjorth-Hansen, B.J. Druker, J.M. Enserink, J.W. Tyner, S. Mustjoki, K. Porkka, Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget 8, 22606–22615 (2017)CrossRefPubMedPubMedCentral

27.

J. Tang, L. Karhinen, T. Xu, A. Szwajda, B. Yadav, K. Wennerberg, T. Aittokallio, Target inhibition networks: predicting selective combinations of druggable targets to block cancer survival pathways. PLoS Comput. Biol. 9, e1003226 (2013)CrossRefPubMedPubMedCentral

28.

B. Yadav, T. Pemovska, A. Szwajda, E. Kulesskiy, M. Kontro, R. Karjalainen, M.M. Majumder, D. Malani, A. Murumägi, J. Knowles, K. Porkka, C. Heckman, O. Kallioniemi, K. Wennerberg, T. Aittokallio, Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci. Rep. 4, 5193 (2015)CrossRef

29.

H. Kuusanmäki, O. Dufva, E. Parri, A.J. van Adrichem, H. Rajala, M.M. Majumder, B. Yadav, A. Parsons, W.C. Chan, K. Wennerberg, S. Mustjoki, C.A. Heckman, Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling. Oncotarget 8, 97516–97527 (2017)CrossRefPubMedPubMedCentral

30.

R. Demsky, J. McCuaig, M. Maganti, K.J. Murphy, B. Rosen, S.R. Armel, Keeping it simple: Genetics referrals for all invasive serous ovarian cancers. Gynecol. Oncol. 130, 329–333 (2013)CrossRefPubMed

31.

A. Lanceley, Z. Eagle, G. Ogden, S. Gessler, K. Razvi, J.A. Ledermann, L. Side, Family history and women with ovarian cancer. Int. J. Gynecol. Cancer 22, 254–259 (2012)CrossRefPubMed

32.

A. George, D. Riddell, S. Seal, S. Talukdar, S. Mahamdallie, E. Ruark, V. Cloke, I. Slade, Z. Kemp, M. Gore, A. Strydom, S. Banerjee, H. Hanson, N. Rahman, Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients. Sci. Rep. 6, 29506 (2016)CrossRefPubMedPubMedCentral

33.

Guidance and guidelines, Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE [Internet]. United Kingdom, National Institute for Health and Clinical Excellence. https://www.nice.org.uk/guidance/cg164/chapter/Recommendations Accessed 11 December 2017

34.

I. Slade, H. Hanson, A. George, K. Kohut, A. Strydom, S. Wordsworth, N. Rahman, A cost analysis of a cancer genetic service model in the UK. J. Community Genet. 7, 185–194 (2016)CrossRefPubMedPubMedCentral

35.

Assembly of the Republic, in Diário da República Eletrónico, Legislação, Lei n.^o 12/2005- Diário da República n.^o 18/2005, Série I-A de 2005–01-26- DRE. 606–611 [Internet]. Portugal, Diário da República Eletrónico. https://dre.pt/web/guest/pesquisa/-/search/624463/details/normal?_search_WAR_drefrontofficeportlet_print_preview=print-preview Accessed 11 December 2017

36.

Assembly of the Republic, in Diário da República Eletrónico, Legislação, Decreto-Lei n.^o 131/2014 – Ministério da Saúde–Regulamenta a Lei n.^o 12/2005, de 26 de janeiro [Internet]. Portugal, Diário da República Eletrónico. http://direitodamedicina.sanchoeassociados.com/arquivo/decreto-lei-n-o-1312014-ministerio-da-saude-regulamenta-a-lei-n-o-122005-de-26-de-janeiro-no-que-se-refere-a-protecao-e-confidencialidade-da-informacao-genetica-as-bases-de-da/ Accessed 11 December 2017

37.

Commissioner of the Press Announcements in FDA, U.S. Food and Drug, Press Announcements. FDA approves first cancer treatment for any solid tumor with a specific genetic feature [Internet]. USA, FDA. https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm560167.htm Accessed 11 December 2017

38.

D.T. Le, J.N. Uram, H. Wang, B.R. Bartlett, H. Kemberling, A.D. Eyring, A.D. Skora, B.S. Luber, N.S. Azad, D. Laheru, B. Biedrzycki, R.C. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, S.M. Duffy, R.M. Goldberg, A. de la Chapelle, M. Koshiji, F. Bhaijee, T. Huebner, R.H. Hruban, L.D. Wood, N. Cuka, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, S. Zhou, T.C. Cornish, J.M. Taube, R.A. Anders, J.R. Eshleman, B. Vogelstein, L.A. Diaz, PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015)CrossRefPubMedPubMedCentral

39.

D.T. Le, J.N. Durham, K.N. Smith, H. Wang, B.R. Bartlett, L.K. Aulakh, S. Lu, H. Kemberling, C. Wilt, B.S. Luber, F. Wong, N.S. Azad, A.A. Rucki, D. Laheru, R. Donehower, A. Zaheer, G.A. Fisher, T.S. Crocenzi, J.J. Lee, T.F. Greten, A.G. Duffy, K.K. Ciombor, A.D. Eyring, B.H. Lam, A. Joe, S.P. Kang, M. Holdhoff, L. Danilova, L. Cope, C. Meyer, S. Zhou, R.M. Goldberg, D.K. Armstrong, K.M. Bever, A.N. Fader, J. Taube, F. Housseau, D. Spetzler, N. Xiao, D.M. Pardoll, N. Papadopoulos, K.W. Kinzler, J.R. Eshleman, B. Vogelstein, R.A. Anders, L.A. Diaz, Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017)CrossRefPubMedPubMedCentral

40.

M. Robson, S.A. Im, E. Senkus, B. Xu, S.M. Domchek, N. Masuda, S. Delaloge, W. Li, N. Tung, A. Armstrong, W. Wu, C. Goessl, S. Runswick, P. Conte, Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N. Engl. J. Med. 377, 523–533 (2017)CrossRefPubMed

41.

European public assessment report (EPAR) in European Medicines Agency (EMA), Science Medicines Health, Human Medicine. Lynparza [Internet]. United Kingdom, EMA. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/003726/human_med_001831.jsp&mid=WC0b01ac058001d124 Accessed 15 December 2017

42.

F.R. Vogenberg, C. Isaacson Barash, M. Pursel, Personalized medicine: part 1: evolution and development into theranostics. P & T 35, 560–576 (2010)

43.

Serviço Nacional de Saúde (SNS), Medicina personalizada na Europa [Internet]. Portugal, SNS. https://www.sns.gov.pt/noticias/2017/10/20/medicina-personalizada-na-europa/ Accessed 18 December 2017

44.

N.L. Bragazzi, From P0 to P6 medicine, a model of highly participatory, narrative, interactive, and "augmented" medicine: some considerations on Salvatore Iaconesi’s clinical story. Patient Prefer Adherence 7, 353–359 (2013)CrossRefPubMedPubMedCentral

45.

E.P. Bottinger, Foundations, promises and uncertainties of personalized medicine. Mt Sinai J. Med. 74, 15–21 (2007)CrossRefPubMed

46.

M.A. Hamburg, F.S. Collins, The path to personalized medicine. N. Engl. J. Med. 363, 301–304 (2010)CrossRefPubMed

47.

M.F. Haward, J.M. Lorenz, Communicating risk under conditions of uncertainty: not as simple as it may seem. Acta Paediatr. 100, 651–652 (2011)CrossRefPubMed

48.

N.J. Schork, Personalized medicine: time for one-person trials. Nature 520, 609–611 (2015)CrossRefPubMed

Title: Genetics of personalized medicine: cancer and rare diseases
Authors: Inês Teles Siefers Alves
Manuel Condinho
Sónia Custódio
Bruna F. Pereira
Rafael Fernandes
Vânia Gonçalves
Paulo J. da Costa
Rafaela Lacerda
Ana Rita Marques
Patrícia Martins-Dias
Gonçalo R. Nogueira
Ana Rita Neves
Patrícia Pinho
Raquel Rodrigues
Eva Rolo
Joana Silva
André Travessa
Rosário Pinto Leite
Ana Sousa
Luísa Romão
Publication date: 01-06-2018
Publisher: Springer Netherlands
Published in: Cellular Oncology / Issue 3/2018
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI: https://doi.org/10.1007/s13402-018-0379-3

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2018

A HIF-independent, CD133-mediated mechanism of cisplatin resistance in glioblastoma cells

Inhibition of autophagy enhances DENSpm-induced apoptosis in human colon cancer cells in a p53 independent manner

Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1

Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer

Diagnostic and prognostic relevance of salivary microRNA-21, -125a, -31 and -200a levels in patients with oral lichen planus - a short report